APOC2 and chronic kidney disease: The iTRAQ-based proteomic method identified potential biomarkers, apolipoprotein C-II (apoC-II) and apolipoprotein C-III (apoC-III), which could be validated in our subsequent studies to predict CV risk in children with CKD.